{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:31:47Z","timestamp":1790011907826,"version":"4.0.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hereditary spastic paraplegias (HSPs) are a heterogeneous group of neurodegenerative diseases in which little is known about the most appropriate clinical outcome assessments (COAs) to capture disease progression. The objective of this study was to prospectively determine disease progression after 4.5\u2009years of follow-up with different clinician-reported (ClinRO) and gait performance outcomes (PerFOs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-six HSP patients (15 SPG4, 5 SPG7, 4 SPG5, 2 SPG3A) participated in this single-center cohort study in which the ClinRO: Spastic Paraplegia Rating Scale; and the PerFOs: 10-meters walking test and timed-up and go (TUG), at self-selected and maximal walking speeds; Locomotor Rehabilitation Index; and 6-min walking test were performed at baseline and after 1.5 (18 patients) and 4.5 (13 patients) years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the 3-year interval between the second and third assessments, significant progressions were only found in PerFOs, while in the overall 4.5\u2009years of follow-up, both PerFOs and ClinROs presented significant progressions. The progression slopes of COAs modeled according to the disease duration allowed the estimation of the annual progression of the outcomes and sample size estimations for future clinical trials of interventions with different effect sizes. TUG at maximal walking speed was the only COA capable of differentiating subjects with a worse compared to a stable\/better impression of change and would require the smallest sample size if chosen as the primary endpoint of a clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings indicate that both performance and clinician-reported outcomes can capture long-term progression of HSPs, with some PerFOs presenting greater sensitivity to change. The presented data are paramount for planning future disease-modifying and symptomatic therapy trials for this currently untreatable group of diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnins.2023.1226479","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T08:58:16Z","timestamp":1695373096000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term progression of clinician-reported and gait performance outcomes in hereditary spastic paraplegias"],"prefix":"10.3389","volume":"17","author":[{"given":"Diana Maria","family":"Cubillos Arcila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Dariva Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ria Feij\u00f3","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa Bielefeldt","family":"Leotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sch\u00fcle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Alexandre","family":"Peyr\u00e9-Tartaruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas Alex Morales","family":"Saute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1519\/JPT.0b013e318264b8ed","article-title":"The test-retest reliability of 10 meters maximal walking speed in older people living in a residential care unit","volume":"36","author":"Adell","year":"2012","journal-title":"J. Geriatr. Phys. Ther."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e200052","DOI":"10.1212\/NXG.0000000000200052","article-title":"Toward the definition of patient-reported outcome measurements in hereditary spastic paraplegia","volume":"9","author":"Amprosi","year":"2023","journal-title":"Neurol. Genet."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2318-14-14","article-title":"Is the timed up and go test a useful predictor of risk of falls in community dwelling older adults: a systematic review and meta-analysis","volume":"2","author":"Barry","year":"2014","journal-title":"BMC Geriatr."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00415-015-7707-6","article-title":"Dalfampridine in hereditary spastic paraplegia: a prospective, open study","volume":"262","author":"B\u00e9reau","year":"2015","journal-title":"J. Neurol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/ageing\/32.3.315","article-title":"Identifying a cut-off point for normal mobility: a comparison of the timed \u201cup and go\u201d test in community-dwelling and institutionalised elderly women","volume":"32","author":"Bischoff","year":"2003","journal-title":"Age Ageing"},{"key":"ref7","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s12311-021-01302-2","article-title":"Progression of functional gait in hereditary spastic paraplegias","volume":"21","author":"Cubillos-Arcila","year":"2022","journal-title":"Cerebellum"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2340\/16501977-1909","article-title":"Functional effects of botulinum toxin type-a treatment and subsequent stretching of spastic calf muscles: a study in patients with hereditary spastic paraplegia","volume":"47","author":"de Niet","year":"2015","journal-title":"J. Rehabil. Med."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1365-2990.2004.00587.3","article-title":"The extent of axonal loss in the long tracts in hereditary spastic paraplegia","volume":"30","author":"DeLuca","year":"2004","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/mds.28523","article-title":"Randomized trial of botulinum toxin type a in hereditary spastic paraplegia - the SPASTOX trial","volume":"36","author":"Diniz de Lima","year":"2021","journal-title":"Mov. Disord."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/brain\/119.5.1487","article-title":"Phenotype of autosomal dominant spastic paraplegia linked to chromosome 2","volume":"119","author":"D\u00fcrr","year":"1996","journal-title":"Brain J. Neurol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"690899","DOI":"10.3389\/fmolb.2021.690899","article-title":"Insights into clinical, genetic, and pathological aspects of hereditary spastic paraplegias: a comprehensive overview","volume":"8","author":"Elsayed","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"ref14","volume-title":"Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments","year":"2022"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/cge.14280","article-title":"Copy number variations in SPAST and ATL1 are rare among Brazilians","volume":"103","author":"Fussiger","year":"2022","journal-title":"Clin. Genet."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"106888","DOI":"10.1016\/j.clineuro.2021.106888","article-title":"Functional gait measures correlate to fear of falling, and quality of life in patients with hereditary spastic paraplegia: a cross-sectional study","volume":"209","author":"Ga\u00dfner","year":"2021","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"22248","DOI":"10.1038\/s41598-021-01635-2","article-title":"Clinical and molecular characterization of a large cohort of childhood onset hereditary spastic paraplegias","volume":"11","author":"Giordani","year":"2021","journal-title":"Sci. Rep."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.nmd.2014.11.011","article-title":"European medicines agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene","volume":"25","author":"Haas","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"8334","DOI":"10.1016\/S0140-6736(83)92879-9","article-title":"Classification of the hereditary ataxias and paraplegias","volume":"1","author":"Harding","year":"1983","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control. Clin. Trials"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Clinical evaluator training group; ACT DMD study group. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/mus.23905","article-title":"The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3389\/fnins.2020.00111","article-title":"Efficacy of a combined treatment of botulinum toxin and intensive physiotherapy in hereditary spastic paraplegia","volume":"14","author":"Paparella","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref9004","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1093\/brain\/awy285","article-title":"Spastic paraplegia due to SPAST mutations is modified by the underlying mutation and sex","volume":"141","author":"Parodi","year":"2018","journal-title":"Brain"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4103\/2468-5658.184750","article-title":"A new integrative approach to evaluate pathological gait: locomotor rehabilitation index","volume":"1","author":"Peyr\u00e9-Tartaruga","year":"2016","journal-title":"Clin. Transl. Degener Dis."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x.12","article-title":"The timed \u201cup & go\u201d: a test of basic functional mobility for frail elderly persons","volume":"39","author":"Podsiadlo","year":"1991","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e1079","DOI":"10.1212\/WNL.0000000000200819","article-title":"Inertial gait sensors to measure mobility and functioning in hereditary spastic paraplegia: a cross-sectional multicenter clinical study","volume":"99","author":"Regensburger","year":"2022","journal-title":"Neurology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e664","DOI":"10.1212\/NXG.0000000000000664","article-title":"Clinical-genetic features influencing disability in spastic paraplegia type 4: a cross-sectional study by the Italian DAISY network","volume":"8","author":"Rossi","year":"2022","journal-title":"Neurol. Genet."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1093\/brain\/awx273","article-title":"Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial","volume":"140","author":"Sch\u00f6ls","year":"2017","journal-title":"Brain"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1212\/01.wnl.0000228242.53336.90","article-title":"The spastic paraplegia rating scale (SPRS): a reliable and valid","volume":"67","author":"Schule","year":"2006","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/ana.24611","article-title":"Hereditary spastic paraplegia: clinicogenetic lessons from 608 patients","volume":"79","author":"Sch\u00fcle","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1590\/0004-282X20160047","article-title":"Translation and validation into Brazilian Portuguese of the spastic paraplegia rating scale (SPRS)","volume":"74","author":"Servelhere","year":"2016","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/S1474-4422(19)30235-2.2","article-title":"Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches","volume":"18","author":"Shribman","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1519\/00139143-200124010-00001","article-title":"Performance and impairment-based assessments among community-dwelling elderly: sensitivity and specificity","volume":"24","author":"Trueblood","year":"2001","journal-title":"Issues Aging"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/s0031-9406(05)61264.11","article-title":"Refining the ten-metre walking test for use with neurologically impaired people","volume":"88","author":"Watson","year":"2002","journal-title":"Physiotherapy"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejpn.2018.10.001","article-title":"Two-minute versus 6-minute walk distances during 6-minute walk test in neuromuscular disease: is the 2-minute walk test an effective alternative to a 6-minute walk test?","volume":"23","author":"Witherspoon","year":"2019","journal-title":"Eur. J. Paediatr. Neurol."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2023.1226479\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T08:58:23Z","timestamp":1695373103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2023.1226479\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":38,"alternative-id":["10.3389\/fnins.2023.1226479"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2023.1226479","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"article-number":"1226479"}}